Company newsCompany release

CRISPR Therapeutics AG CRSP

CRISPR Therapeutics presents Phase 1b CTX310 data at AHA 2026

A single-course treatment with CTX310 produced mean reductions from baseline of 65% in ANGPTL3 and 63% in triglycerides at Day 30 in patients with severe hypertriglyceridemia.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

On November 9, 2026, CRISPR Therapeutics presented clinical data from its Phase 1b trial of CTX310, an investigational in vivo CRISPR/Cas9 gene editing therapy that acts on ANGPTL3, in a late-breaking oral presentation at the American Heart Association Scientific Sessions 2026. The company said CTX310 was well tolerated, with no treatment-related serious adverse events and no clinically relevant elevations in liver transaminases.

Key facts

Mean reduction in ANGPTL3 at Day 30
65% from baseline
Mean reduction in triglycerides at Day 30
63% from baseline
Median baseline triglycerides
Above 1,000 mg/dL
Presentation
Late-breaking oral presentation at AHA Scientific Sessions 2026

All CRSP news

Source: The company's release on GlobeNewswire, November 9, 2026.

Written by GetSignal with AI from the company's press release. How we make news

Not investment advice.

More company news

CRISPR Therapeutics AG first, then the newest

All company news